All In Biotech

Drug Trial Radar · NCT00077610

A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.

Last checked: Nov 20, 2026Latest source record: Jan 13, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 673 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

673

Actual

Start

Feb 2004

Primary completion

Aug 2005

Study completion Aug 2005

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Feb 13, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the efficacy and safety of intravenous Mircera, given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving iv epoetin. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.

Conditions

  • Anemia

Interventions

  • Epoetin alfa or betaDrug

    intravenously 3 times weekly for 52 weeks, as prescribed

  • RO0503821 (1x/2 Weeks)Drug

    60, 100, or 180 microgram (mcg) (starting dose) once every two weeks intravenously for 52 weeks.

  • RO0503821 (1x/4 Weeks)Drug

    120, 200 or 360 mcg (starting dose) once every four weeks intravenously for 52 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change in Hemoglobin (Hb) Concentration From Baseline to Evaluation PeriodTime frame: Baseline, Week 29 to Week 36

Locations

99 sites in 8 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Mobile, Alabama

  • Site not named

    Montgomery, Alabama

  • Site not named

    Encino, California

  • Site not named

    Irvine, California

  • Site not named

    Los Angeles, California

  • Site not named

    Monterey Park, California

  • Site not named

    Riverside, California

  • Site not named

    Sacramento, California

  • Site not named

    San Diego, California

  • Site not named

    San Diego, California

  • Site not named

    San Francisco, California

  • Site not named

    San Jose, California

  • Site not named

    Colorado Springs, Colorado

  • Site not named

    Denver, Colorado

  • Site not named

    Lakewood, Colorado

  • Site not named

    Ocala, Florida

  • Site not named

    Pembroke Pines, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Augusta, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Maywood, Illinois

  • Site not named

    Louisville, Kentucky

  • Site not named

    Covington, Louisiana

  • Site not named

    Boston, Massachusetts

  • Site not named

    Boston, Massachusetts

  • Site not named

    Springfield, Massachusetts

  • Site not named

    Detroit, Michigan

  • Site not named

    Brooklyn Center, Minnesota

  • Site not named

    Paterson, New Jersey

  • Site not named

    Albuquerque, New Mexico

  • Site not named

    Brooklyn, New York

  • Site not named

    Great Neck, New York

  • Site not named

    Mineola, New York

  • Site not named

    New York, New York

  • Site not named

    New York, New York

  • Site not named

    Stony Brook, New York

  • Site not named

    The Bronx, New York

  • Site not named

    Chapel Hill, North Carolina

  • Site not named

    Raleigh, North Carolina

Showing 40 of 99 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.